Rise Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Rise Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-134	Closed	-$17.7K	–	773
2025 Q3	$17.7K	Hold	134	–	–	0.01%	657
2025 Q2	$14.2K	Hold	134	–	–	0.01%	770
2025 Q1	$16.6K	Sell	134 -75	-36%	-$9.78K	0.01%	620
2024 Q4	$25.7K	Sell	209 -3	-1%	-$354	0.01%	486
2024 Q3	$23.6K	Hold	212	–	–	0.01%	573
2024 Q2	$22.6K	Hold	212	–	–	0.01%	546
2024 Q1	$25.5K	Buy	212 +203	+2,256%	+$24.9K	0.01%	480
2023 Q4	$1.11K	Hold	9	–	–	﹤0.01%	514
2023 Q3	$1.17K	Hold	9	–	–	﹤0.01%	520
2023 Q2	$1.12K	Hold	9	–	–	﹤0.01%	568
2023 Q1	$1.32K	Hold	9	–	–	﹤0.01%	624
2022 Q4	$1.43K	Hold	9	–	–	﹤0.01%	611
2022 Q3	$1K	Hold	9	–	–	﹤0.01%	632
2022 Q2	$1K	Hold	9	–	–	﹤0.01%	640
2022 Q1	$1K	Hold	9	–	–	﹤0.01%	609
2021 Q4	$1.15K	Buy	+9	New	+$1.18K	﹤0.01%	591

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Rise Advisors's JAZZ Position: Q4 2025 in Review

Rise Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 134 shares — an estimated $17.7K sold.

Rise Advisors first reported a position in JAZZ in Q4 2021 and held it in 16 quarters. The position peaked at $25.7K in Q4 2024. 573 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

Rise Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 134 Jazz Pharmaceuticals shares in Q4 2025, an estimated $17.7K.
Rise Advisors first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 16 quarters.
Rise Advisors's Jazz Pharmaceuticals position peaked at $25.7K in Q4 2024.
573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.